TAVI will become a valid alternative to surgical aortic valve replacement (SAVR) if not the preferred therapy for most patients including lower risk patients.

The use of TAVR in low-risk patients with severe aortic stenosis is being explored as an alternative to surgical aortic valve replacement (SAVR). Recent results ...

8 апр. 2024 г. · Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as ...

21 мар. 2023 г. · These data indicate that TAVI remains a safe and effective alternative to SAVR in low-risk patients at 3 years. Follow-up will be continued to ...

It is reasonable to proceed with TAVI in low-risk octogenarians and it might be reasonable to start considering it in patients ≥75 years old, probably soon.

24 окт. 2023 г. · When published 4 years ago, both PARTNER 3 trial and the Evolut Low Risk trial were seen as big wins for TAVI in patients at low risk for death ...

In the PARTNER 3 Trial, TAVI, compared with surgery, resulted in superior clinical outcomes, improved quality of life and faster discharge for sAS patients.

23 нояб. 2023 г. · We randomly assigned patients with severe, symptomatic aortic stenosis and low surgical risk to undergo either TAVR or surgery.

Two landmark trials demonstrated TAVI was non-inferior to SAVR in low surgical risk patients but had higher rates of pacemakers and paravalvular leaks.

Evolut™ TAVI is the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at two years.